Serum vascular endothelial growth factor associated with the progression of granulosa cell tumor: a report of two cases.
Chemotherapy
Granulosa cell tumor
Vascular endothelial growth factor
Journal
Journal of ovarian research
ISSN: 1757-2215
Titre abrégé: J Ovarian Res
Pays: England
ID NLM: 101474849
Informations de publication
Date de publication:
14 Jun 2023
14 Jun 2023
Historique:
received:
21
12
2022
accepted:
30
05
2023
medline:
16
6
2023
pubmed:
15
6
2023
entrez:
14
6
2023
Statut:
epublish
Résumé
Granulosa cell tumors (GCTs) account for approximately 2% of ovarian malignancies and are considered a rare type of ovarian cancer. GCTs are characterized by irregular genital bleeding after menopause due to female hormone production as well as late recurrence around 5-10 years after initial treatment. In this study, we investigated two cases of GCTs to find a biomarker that can be used to evaluate the treatment and predict recurrence. Case 1 was a 56-year-old woman who presented to our hospital with abdominal pain and distention. An abdominal tumor was found, and GCTs were diagnosed. Serum vascular endothelial growth factor (VEGF) levels decreased after surgery. Case 2 involved a 51-year-old woman with refractory GCTs. Carboplatin-paclitaxel combination therapy and bevacizumab were administered after the tumor resection. After chemotherapy, a decline in VEGF levels was observed, but serum VEGF levels increased again with disease progression. VEGF expression may be of clinical importance in GCTs as a clinical biomarker for disease progression, which may be used to determine the efficacy of bevacizumab against GCTs.
Sections du résumé
BACKGROUND
BACKGROUND
Granulosa cell tumors (GCTs) account for approximately 2% of ovarian malignancies and are considered a rare type of ovarian cancer. GCTs are characterized by irregular genital bleeding after menopause due to female hormone production as well as late recurrence around 5-10 years after initial treatment. In this study, we investigated two cases of GCTs to find a biomarker that can be used to evaluate the treatment and predict recurrence.
CASE PRESENTATION
METHODS
Case 1 was a 56-year-old woman who presented to our hospital with abdominal pain and distention. An abdominal tumor was found, and GCTs were diagnosed. Serum vascular endothelial growth factor (VEGF) levels decreased after surgery. Case 2 involved a 51-year-old woman with refractory GCTs. Carboplatin-paclitaxel combination therapy and bevacizumab were administered after the tumor resection. After chemotherapy, a decline in VEGF levels was observed, but serum VEGF levels increased again with disease progression.
CONCLUSIONS
CONCLUSIONS
VEGF expression may be of clinical importance in GCTs as a clinical biomarker for disease progression, which may be used to determine the efficacy of bevacizumab against GCTs.
Identifiants
pubmed: 37316921
doi: 10.1186/s13048-023-01197-z
pii: 10.1186/s13048-023-01197-z
pmc: PMC10265796
doi:
Substances chimiques
Vascular Endothelial Growth Factor A
0
Bevacizumab
2S9ZZM9Q9V
Vascular Endothelial Growth Factors
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112Subventions
Organisme : Grant-in-Aid for Scientific Research from the Ministry of Education
ID : 19K09834
Informations de copyright
© 2023. The Author(s).
Références
J Ovarian Res. 2022 May 25;15(1):65
pubmed: 35610706
J Clin Oncol. 2003 Mar 15;21(6):1180-9
pubmed: 12637488
J Ovarian Res. 2018 Feb 06;11(1):13
pubmed: 29409506
Eur J Endocrinol. 2011 Jan;164(1):115-22
pubmed: 21041381
Gynecol Oncol. 2021 Nov;163(2):269-273
pubmed: 34454726
Gynecol Oncol. 2009 Sep;114(3):431-6
pubmed: 19524286
J Clin Endocrinol Metab. 2011 Dec;96(12):E1973-81
pubmed: 21994955
Indian J Surg Oncol. 2013 Mar;4(1):37-47
pubmed: 24426698
Gynecol Oncol. 2008 Dec;111(3):527-9
pubmed: 18710781
Onco Targets Ther. 2018 Mar 07;11:1315-1322
pubmed: 29563810
Cancer. 2014 Feb 1;120(3):344-51
pubmed: 24166194
J Ovarian Res. 2018 Mar 27;11(1):25
pubmed: 29587835
Oncotarget. 2018 Jul 17;9(55):30552-30560
pubmed: 30093968
Int J Gynecol Cancer. 2019 Mar;29(3):560-565
pubmed: 30833441
Anticancer Res. 2010 Nov;30(11):4767-8
pubmed: 21115938
J Ovarian Res. 2014 Sep 06;7:88
pubmed: 25297715